Status:
COMPLETED
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
Brief Summary
The objectives of this Post Marketing Surveillance (PMS) are: * Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs S...
Eligibility Criteria
Inclusion
- Patients suffering from primary RLS who are eligible for Pramipexol (PPX) treatment could be included into the study
- Patients not pre-treated with any dopaminergic agent (de novo patients) or patients pre-treated with dopaminergic medication
- Male of female patients of any age
Exclusion
- The treating physicians are asked to consider the regulations described in the Summary of Product Characteristics (SmPC) for the treatment with pramipexole
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
2644 Patients enrolled
Trial Details
Trial ID
NCT02248155
Start Date
April 1 2006
Last Update
September 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.